Looking for clear facts on retatrutide side effects? This guide reviews what phase 2 and phase 3 trials actually reported, including nausea, diarrhea, vomiting, constipation, heart rate changes, and a skin sensation called dysesthesia.
You will see how often people stopped treatment because of side effects at each trial dose. We also explain retatrutide dosing and retatrutide dosage in published trials, why no safe retatrutide dosage calculator exists for home use, and what is known about retatrutide cost.
A side-by-side look at retatrutide vs tirzepatide shows how the two drugs compare on weight loss and tolerability. Retatrutide is an investigational drug from Eli Lilly. It is not FDA-approved, and products sold online as retatrutide are unverified.
This article uses trial data only, avoids hype, and gives no personal dosing advice. Read it, then talk with a licensed healthcare provider about your own health, risks, and options before you act on anything you read online.
Key Takeaways
- Retatrutide is investigational. It is not FDA-approved and is legally available only in clinical trials.
- The most common retatrutide side effects are stomach and gut symptoms, mostly during dose increases.
- In TRIUMPH-1, 11.3% of people on the 12 mg dose stopped because of side effects, versus 4.9% on placebo.
- Dysesthesia, an altered skin sensation, is a newer signal not seen with older drugs in the class.
- No approved retatrutide dosage calculator or retail price exists. Online sellers are unverified.
- In trials, retatrutide vs tirzepatide looks like more weight loss but a less clear tolerability picture.
Why Retatrutide Side Effects Matter Right Now
Interest in retatrutide side effects has grown fast. Phase 3 results arrived in 2026. Headlines focused on record weight loss.
Fewer headlines explained the downsides. That is the gap this guide fills.
For many people, tolerability matters as much as results. A drug that works but makes you too sick to continue is not much help.
You will see what trials reported, in plain language. We also cover dosing, cost, and how the drug compares with tirzepatide. Where data is missing, we say so.
What Is Retatrutide?
Retatrutide is an experimental once-weekly injection from Eli Lilly. It is a “triple agonist.” That means it activates three hormone receptors: GIP, GLP-1, and glucagon.
GLP-1 and GIP help control appetite and blood sugar. Glucagon may raise energy use. That third action is what sets it apart.
The glucagon part may also explain some of the retatrutide side effects that older drugs do not show. This is a leading idea, not a proven fact.
Is Retatrutide FDA-Approved?
No. Retatrutide is not approved by the FDA or any major regulator. Lilly has said it plans to submit an application in the first quarter of 2027.
A filing is not an approval. Review usually takes many months. Timelines can change.
FDA guidance also says retatrutide cannot be used in compounding under federal law. For safety and legal details, see this federal drug safety and regulatory resource.
The Trials Behind the Data
Most of what we know comes from three groups of studies.
- Phase 2 (published 2023): A 48-week trial that showed up to 24.2% weight loss at the top dose.
- TRIUMPH-4 (reported December 2025): People with obesity and knee osteoarthritis. The 12 mg dose led to about 28.7% weight loss at 68 weeks.
- TRIUMPH-1, -2, and -3 (2026): Larger phase 3 trials in obesity, type 2 diabetes, and obesity with heart disease.
The key peer-reviewed source is the phase 3 trial results published in a leading medical journal. Some figures in this article come from sponsor announcements and medical news coverage, so treat them as company-reported until the full papers are reviewed.
TRIUMPH-1 at a Glance
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and no diabetes. It ran 80 weeks. Doses were 4 mg, 9 mg, or 12 mg once weekly, or placebo.
People started at 2 mg and moved up every four weeks. At 12 mg, the average weight loss was 28.3% using the efficacy estimand. A different analysis method reported about 25%.
Both numbers are large. But they say nothing about how people felt along the way. That is where retatrutide side effects come in.
Retatrutide Side Effects: What Trials Reported
The overall safety profile was described as similar to other incretin drugs. Stomach and gut effects led the list. Most were mild to moderate.
But “similar to the class” does not mean “easy.” At high doses, many people had symptoms.
Most Common Retatrutide Side Effects by Dose
The table below shows nausea in TRIUMPH-1, as reported in medical news coverage of the sponsor data.
| Dose | Nausea | Stopped due to side effects |
|---|---|---|
| Placebo | 14.8% | 4.9% |
| 4 mg | 28.6% | 4.1% |
| 9 mg | 38.4% | 6.9% |
| 12 mg | 42.4% | 11.3% |
The pattern is clear. Higher dose means more nausea and more dropouts. The 4 mg group stopped less often than placebo.
Stomach and Gut Symptoms
At 12 mg in TRIUMPH-1, these were reported:
- Nausea: 42.4%
- Diarrhea: 32.0%
- Constipation: 26.1%
- Vomiting: 25.3%
Decreased appetite was also common. That is partly the drug doing its job.
These retatrutide side effects usually peaked during dose increases. In phase 2, gut symptoms were the main reason people left the study. They mostly appeared while the dose was being raised.
Dysesthesia: A Newer Signal
Dysesthesia means an odd or uncomfortable skin sensation. People describe tingling, burning, or heightened touch.
It was not seen in phase 2. It showed up in phase 3. In TRIUMPH-4, secondary summaries report it in roughly one in five people at 12 mg.
Most cases were described as mild to moderate. Many resolved during treatment. The cause is not confirmed.
Older GLP-1 and GIP drugs have not shown it at similar rates. That makes it one of the more closely watched retatrutide side effects.
Trial length, how symptoms were recorded, and the study population may all play a role. More data is needed.
Heart Rate and Blood Pressure
Phase 2 showed a dose-related rise in resting heart rate. At 12 mg it was roughly 7 beats per minute, peaking near week 24. It then drifted back toward baseline.
This is larger than rises reported with some approved drugs in the class. The glucagon action is the likely reason.
On the plus side, TRIUMPH-1 reported lower systolic blood pressure, lower triglycerides, and lower inflammation markers. Heart rate remains something clinicians watch, especially in people with rhythm problems.
No increase in serious cardiac events was reported in the sources reviewed. Long-term safety data is still limited.
Other Reported Events
Some people reported upper respiratory infections and urinary tract infections. Most were not serious.
What we do not know yet is just as important. Long-term effects beyond about two years are not established. Effects in pregnancy, in children, and in older adults with many conditions are not well studied.
How Often Do People Stop Because of Side Effects?
Discontinuation is a useful, honest measure. It shows how many people could not tolerate the drug.
In TRIUMPH-1, 11.3% stopped at 12 mg because of side effects. That was 6.9% at 9 mg and 4.1% at 4 mg. Placebo was 4.9%.
In phase 2, dropout due to side effects ranged from 6% to 16% across retatrutide groups. Secondary summaries put the TRIUMPH-4 figure at 12 mg at 18.2%.
Why the range? Differences in population, trial length, and dose escalation matter. A slower climb generally helps.
This is why many experts see lower doses as a possible practical option. Nearly 19% weight loss at 4 mg, with fewer dropouts, is a real trade-off to weigh.
Who May Face Higher Risk?
Trials do not fully tell us who is most at risk. But some groups deserve extra caution in general with this drug class:
- People with heart rhythm conditions or uncontrolled high blood pressure
- People with a history of pancreatitis or gallbladder disease
- People who are pregnant, planning pregnancy, or breastfeeding
- People with severe stomach or gut disease
- People who are already underweight or at risk of malnutrition
This list reflects general class cautions, not retatrutide-specific labeling. No approved label exists yet. Only a clinician who knows your history can judge your risk.
Retatrutide Dosing: What Trials Used
Retatrutide dosing in studies is controlled and supervised. Participants receive a once-weekly injection under the skin.
There is no approved dosing schedule. Anything you read online as a “protocol” is not medical guidance.
Here is what published trials describe at a high level:
- Treatment starts low, at 2 mg weekly in TRIUMPH-1.
- Doses rise every four weeks in steps.
- Final doses studied were 4 mg, 9 mg, and 12 mg.
The slow climb exists for a reason. It gives the body time to adjust and lowers gut symptoms.
Do not copy trial retatrutide dosing at home. Trial drug is made, tested, and monitored under strict rules. Clinicians watch participants and can stop treatment if problems appear.
Retatrutide Dosage: Understanding the Numbers
When people search for retatrutide dosage, they often want one number. There is no single correct number.
In trials, the target dose was set by the study plan. It was not chosen by participants. Results differ by dose, and so do retatrutide side effects.
Three points help put the numbers in context:
- Higher retatrutide dosage in trials meant more weight loss on average.
- Higher retatrutide dosage also meant more nausea and more dropouts.
- Trial doses apply to trial drug, not to products sold online.
The last point matters most. A vial labeled “12 mg” from an unverified seller may hold a different amount. It may hold something else entirely.
If an approved product reaches the market, its label will state the official retatrutide dosage. Until then, no one can responsibly give you a personal dose.
Retatrutide Dosage Calculator: Why There Is No Safe One
Searches for a retatrutide dosage calculator are rising. People want to turn a powder vial into a dose in units.
Here is the honest answer. No approved retatrutide dosage calculator exists. We do not provide one, and you should be careful with any you find.
The Problems With Online Calculators
- They assume the vial contains what the label says. That is often unproven.
- They require mixing powder with liquid. Small math or measuring errors can mean a large dosing error.
- They cannot account for your health, other medicines, or tolerance.
- They are not reviewed by any regulator.
A wrong dose can raise the risk of severe vomiting, dehydration, and other harm. Any retatrutide dosage calculator gives false confidence when the product itself is unverified.
If you want to use a drug like this, the safe path is a clinical trial or, after approval, a prescription. A pharmacist can handle mixing and measuring questions for approved products.
Retatrutide Cost: What We Know
Retatrutide cost is a common question. The honest answer is that no official retail price exists.
Lilly has not announced pricing. The drug is not sold in pharmacies. It is not covered by insurance because it is not approved.
In trials, participants do not pay for study drug. That is the only legal access today.
Why Online Prices Are Not Reliable
You may see prices listed online. These come from sellers of “research use only” products. They are not a real retatrutide cost for medicine.
Cheap does not mean safe. You may pay for a product that is under-dosed, contaminated, or not retatrutide at all.
Once approved, final pricing will depend on Lilly, insurers, and the market. Other drugs in this class have had very different prices by country and coverage plan. Any retatrutide cost estimate today is a guess.
Retatrutide vs Tirzepatide: How They Compare
Tirzepatide is the closest approved comparison. It is a dual agonist (GIP and GLP-1) sold as Mounjaro and Zepbound. Semaglutide, sold as Ozempic and Wegovy, is a GLP-1 only drug.
A fair retatrutide vs tirzepatide comparison has one big limit: no head-to-head trial has reported. Numbers come from different studies, with different people and lengths.
| Feature | Retatrutide | Tirzepatide |
|---|---|---|
| Mechanism | GIP, GLP-1, glucagon | GIP, GLP-1 |
| Status | Investigational | FDA-approved |
| Top-dose weight loss (trials) | About 25% to 28% at 80 weeks | About 22.5% at 72 weeks (SURMOUNT-1) |
| Stopped due to side effects | 11.3% at 12 mg (TRIUMPH-1) | About 6% at top dose (SURMOUNT-1) |
| Heart rate rise | Larger signal | Smaller |
| Dysesthesia | Reported in phase 3 | Not a known signal |
| Dosing | Once weekly, trial only | Once weekly, label-guided |
| Price | Not announced | Set by maker and insurers |
On weight loss, retatrutide looks stronger in these trials. On tolerability, the picture is less clear. Dropout was higher at 12 mg.
The key point in retatrutide vs tirzepatide is the evidence gap. Tirzepatide has years of real-world safety data. Retatrutide does not.
That makes the retatrutide vs tirzepatide debate partly about certainty. An approved drug with known risks may be a better choice than an unproven one with a bigger headline number.
The Risk of Unregulated Retatrutide Products
Because demand is high, many sites sell “retatrutide.” These are not approved medicines.
The FDA has stated that retatrutide has not been found safe and effective for any condition. Lilly has said black-market products are not the trial drug.
Media reports in October 2026 said the FDA received two reports of deaths after people used products sold as retatrutide. The FDA did not say whether it verified them. A report is a warning sign, not proof of cause.
Risks of unverified products include:
- Wrong or unknown strength
- Contamination or poor sterility
- Wrong ingredient
- No quality testing
- No support if something goes wrong
These risks can make retatrutide side effects worse and harder to predict. For a broader plain-language view of safe weight management, see this overview of weight loss options and safety.
When to Seek Medical Care
Contact a clinician if you have any drug-related symptoms that worry you. Seek urgent care for:
- Severe or lasting stomach pain, especially with vomiting
- Signs of dehydration, such as dizziness or very dark urine
- Fast or irregular heartbeat, or chest pain
- Swelling of the face or throat, or trouble breathing
- Yellowing of the skin or eyes
Call emergency services for chest pain, severe allergic signs, or fainting.
If you took an unverified product, tell your clinician exactly what you used. Honest details help them treat you.
Retatrutide Timeline: What Happens Next
Here is where things stand as of October 29, 2026.
- Phase 3 results for obesity, type 2 diabetes, and heart disease populations have been reported.
- Lilly plans to submit an application in the first quarter of 2027.
- Reports note a dispute with the FDA over which application pathway applies.
- Approval, if granted, would likely follow after a review of many months.
There is no confirmed approval date. Anyone claiming one is guessing. To follow public interest over time, you can check this live search interest trend for retatrutide.
Frequently Asked Questions
What are the most common retatrutide side effects?
Nausea, diarrhea, vomiting, and constipation lead the list. These retatrutide side effects are usually mild to moderate and tend to peak when the dose goes up.
Are retatrutide side effects serious?
Most reported effects were not serious. But some people stopped treatment, and rarer risks may not show until more people use the drug. Long-term data is limited.
Is there a safe retatrutide dosage calculator?
No. No approved retatrutide dosage calculator exists. The drug is not approved, so no regulator-reviewed dosing tool exists for home use.
How much does retatrutide cost?
There is no official price. The retatrutide cost shown by online sellers is for unverified products and is not a reliable guide.
Is retatrutide stronger than tirzepatide?
In separate trials, retatrutide showed higher average weight loss. But no head-to-head study exists, so the retatrutide vs tirzepatide question is not fully settled.
Can I follow the trial dosing myself?
No. Retatrutide dosing in trials is supervised and uses controlled trial drug. Copying it with an online product is unsafe.
Do side effects go away?
For many people, gut symptoms improve after dose increases settle. Some effects, like dysesthesia, were reported as resolving during treatment, but this varies and data is limited.
Can I join a clinical trial?
Possibly. Eligibility rules apply, and a listing is not a guaranteed spot. Ask your clinician about registered studies.
Conclusion
The data on retatrutide side effects shows a powerful drug with real trade-offs. Weight loss was large. Gut symptoms were common. Dysesthesia and heart rate changes are signals to watch.
The retatrutide dosage that worked in trials was given under supervision. There is no safe home version, no retatrutide dosage calculator you can trust, and no official retatrutide cost yet.
In the retatrutide vs tirzepatide debate, the bigger number is not the whole story. Safety record and certainty matter too.
If you are interested in this drug class, speak with a licensed healthcare provider about approved options. Stay informed as results are published and an approval decision is made.
Medical disclaimer: This content is for information only. It does not replace advice from a licensed healthcare provider. Do not start, stop, or change any medicine without professional guidance. Retatrutide is investigational and not FDA-approved. If you have a medical emergency, call your local emergency number.
